Navigation Links
Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
Date:9/17/2007

NEW YORK, Sept. 17 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that I. Craig Henderson, MD, the Company's President, will present an overview of the Company's cancer pipeline at the upcoming Bank of America 37th Annual Investment Conference in San Francisco. Dr. Henderson's presentation will take place on Wednesday, September 19th at 8:30 am PT.

Dr. Henderson's presentation will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Cannavoices , Inc., ... unprecedented digital video and broadcast initiative. Produced by filmmakers, the multi-platform initiative aims ... legal medical cannabis stories ever assembled. , Cannavoices profiles Advocates, Patients, Entrepreneurs, ...
(Date:6/29/2015)... and Manhattan, KS (PRWEB) , ... June 29, ... ... acquired US PATENT 7736892 B2. Under the terms of the agreement, MediVet will ... Cord Matrix Stem Cells (UCMSCs). MB-007 is currently in pre-clinical development as a ...
(Date:6/29/2015)... 2015  AACC, a global scientific and medical ... medicine, is pleased to announce that the impact ... has increased to 7.9 in the 2014 Thomson ... Clinical Chemistry in the top 3% of ... of the research it publishes on laboratory medicine ...
(Date:6/29/2015)... June 29, 2015 According to a ... XNA), by Application (Diagnostics, Therapeutics, R&D), by Technology (SELEX, Other ... Companies, CRO) - Global Forecast to 2020", published by MarketsandMarkets, ... by 2020 from $107.56 Million in 2015, at a CAGR ... ables and 67 F igures spread through ...
Breaking Biology Technology:Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4
... Key Secondary Endpoints,NEW YORK, March 10 Intra-Cellular Therapies, ... Phase II trial in patients with Sleep Maintenance Insomnia ... increased slow wave sleep and decreased the duration of ... meeting the prespecified primary and key secondary endpoints of ...
... March 9 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... positive clinical study results for its Bio-Seal(TM) Lung ... Interventional Radiologists Annual Scientific Meeting in San Diego, ... of Bio-Seal in patients undergoing lung biopsy procedures ...
... 9 Former Presidential candidate Gary Bauer on Monday called ... embryonic stem cell research "evidence that ideology is the goal ... a tragedy, as lives will be lost and not saved ... Values made the following statement: "It,s tragic that Barack Obama ...
Cached Biology Technology:Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 3Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 4Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 5Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 6Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 7Angiotech announces positive results from Bio-Seal(TM) clinical study 2Angiotech announces positive results from Bio-Seal(TM) clinical study 3Angiotech announces positive results from Bio-Seal(TM) clinical study 4Angiotech announces positive results from Bio-Seal(TM) clinical study 5
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical ... use solutions, headquartered in Springville, Utah , ... California corporation with locations in Santa ... Rica ). This acquisition will incorporate MedConx,s ... ATL Technology,s existing facility in Costa Rica ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/23/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/vq2k2f/bodyworn ... "Body-Worn Temperature Sensors Market - Global Industry Analysis, ... 2020" report to their offering. ... body-worn temperature sensors market. The global body-worn temperature ... of types, care setting, patient demographic, applications and ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... A team from the National Institute of Standards ... Guard on a coordinated effort to train emergency first ... securing reliable samples of suspected biothreats. The project, dubbed ... first responders at the state, local and federal levels ...
... in the journal Annals of Botany , Professor Douglas ... in the ground could harvest more carbon from the air, ... levels. In principle, any crops could be treated in ... for the environment. Although the amount of carbon presently ...
... Nobel Prize for nerve growth factor was awarded more than ... use growth factor clinically. University of Pittsburgh Professor Yadong ... factor to regrow blood vessels. His research, which could be ... death in the Western world, is published this week in ...
Cached Biology News:Operation Vigilant Sample: First responder training for suspicious powders 2Crop breeding could 'slash CO2 levels' 2Regrowing blood vessels with a potent molecule 2Regrowing blood vessels with a potent molecule 3Regrowing blood vessels with a potent molecule 4
... performance spectral scanning multimode reader with ... advanced SkanIt Software it offers superior ... assay development. Varioskan provides unlimited wavelength ... and photometric assays and a dispenser ...
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
... Effectively condenses and traps a wide variety of ... pump oil. Easy-to-use glass condensation flask (GCF400) allows ... contained jar for easy draining. Rapid cooling time ... glass flask for quick solvent changes ...
... Assays in Tris buffer, pH 10.2 give ... buffer system. Assays in diethanolamine buffer, pH ... the glycine buffer system. Protein determined by ... buffer salts Preparation Unit Definition: One unit ...
Biology Products: